Form S-3

INNOVATE Corp. Announces Closing of Rights Offering

Retrieved on: 
Wednesday, April 24, 2024
Sale, Prospectus, Panzer corps, Form S-3, Computershare, Form, Exercise, Investment, Security (finance)

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today the closing of its successful rights offering, which expired at 5:00 p.m., New York City time, on April 19, 2024.

Key Points: 
  • NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today the closing of its successful rights offering, which expired at 5:00 p.m., New York City time, on April 19, 2024.
  • This includes the approximately 6.3 thousand shares of preferred stock issued in connection with the closing of the rights offering and the 9.0 thousand shares already purchased as part of an equity advance arrangement under the Investment Agreement (the “equity advance”).
  • After giving effect to the rights offering, the Company will have 85.2 million shares of common stock issued and outstanding.
  • The rights offering was made only by means of a prospectus and a related prospectus supplement, copies of which were distributed to all eligible rights holders as of the rights offering record date and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Wednesday, April 24, 2024
Sale, Prospectus, J.P. Morgan & Co., RBC Capital Markets, Broadridge Financial Solutions, Morgan Stanley, Vesey Street, Canaccord Genuity, Security (finance), SVB Securities, Form S-3, CNS, Form, Exercise, Therapy, Varick Street, Equity capital markets, Cantor, 2nd Floor, State Street, Central nervous system, BofA Securities, Attention, Telephone, File, Needham & Company

All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.
  • J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.
  • Cantor, Mizuho, Canaccord Genuity and Needham & Company acted as co-managers for the offering.
  • The public offering was made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the “SEC”) and became effective upon filing.

Grayscale Investments® Files S-3 Registration Statement for Grayscale Ethereum Trust

Retrieved on: 
Tuesday, April 23, 2024
Sale, Prospectus, ETF, OTCQX, Risk, Grayscale, Trust, Form S-3, Form, Digital, Grayscale Investments, Investment, Cryptocurrency

Following NYSE Arca's filing of Form 19b-4 for Grayscale Ethereum Trust, Grayscale filed the Form S-3, another key filing requiring regulatory approval in the firm’s effort to uplist ETHE to NYSE Arca as a spot Ethereum ETF*.

Key Points: 
  • Following NYSE Arca's filing of Form 19b-4 for Grayscale Ethereum Trust, Grayscale filed the Form S-3, another key filing requiring regulatory approval in the firm’s effort to uplist ETHE to NYSE Arca as a spot Ethereum ETF*.
  • A registration statement relating to the shares has been filed with the SEC, but has not yet been declared effective.
  • Grayscale Investments, LLC (“Grayscale”) is the sponsor of Grayscale Ethereum Trust (the “Trust”) .
  • The Trust holds Ethereum; however, an investment in the Trust is not a direct investment in Ethereum.

INNOVATE Corp. Announces Preliminary Results of Rights Offering

Retrieved on: 
Monday, April 22, 2024
Sale, Prospectus, Panzer corps, Form S-3, Computershare, Form, Investment, Security (finance)

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today the preliminary results of its successful rights offering, which expired at 5:00 p.m., New York City time, on April 19, 2024 (the “expiration date”).

Key Points: 
  • NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE), a diversified holding company, announced today the preliminary results of its successful rights offering, which expired at 5:00 p.m., New York City time, on April 19, 2024 (the “expiration date”).
  • The results of the rights offering are preliminary and subject to change pending finalization of subscription procedures by the subscription agent.
  • The Company expects to issue a press release on April 24, 2024, to announce the final results of the rights offering.
  • The rights offering was made only by means of a prospectus and a related prospectus supplement, copies of which were distributed to all eligible rights holders as of the rights offering record date and may also be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the rights offering.

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on: 
Thursday, April 18, 2024
Sale, Prospectus, J.P. Morgan & Co., RBC Capital Markets, Broadridge Financial Solutions, Morgan Stanley, Vesey Street, Canaccord Genuity, Security (finance), SVB Securities, Form S-3, CNS, Form, Therapy, Varick Street, Equity capital markets, Cantor, 2nd Floor, State Street, Central nervous system, BofA Securities, Attention, Telephone, File, Needham & Company

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
  • Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions.
  • J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.

AMPG Files For Shelf Registration To Replace Expired Identical Shelf Without Dilution, Reinforcing Financial Stability

Retrieved on: 
Tuesday, April 16, 2024
Form, Sale, Financial management, Prospectus, Form S-3, Growth, Security (finance)

However, AMPG is not selling any securities from the shelf registration statement at this time.

Key Points: 
  • However, AMPG is not selling any securities from the shelf registration statement at this time.
  • The shelf registration comes as a strategic move to maintain agility in capital markets and bolster the company's ability to respond swiftly to potential future financing needs.
  • Shelf registration is a common practice among publicly traded companies, allowing them to register securities for future sale over a specified period.
  • By re-filing for its shelf registration, AMPG affirms its commitment to responsible financial management and proactive planning for future growth opportunities.

Asset Entities Announces Filing of S-3 Shelf Registration Statement

Retrieved on: 
Tuesday, April 16, 2024
ASST, Form, Sale, Discord, Form S-3, Social media, Security (finance)

Once the registration statement becomes effective, Asset Entities may offer to the public from time to time, in one or more offerings, shares of class B common stock, preferred stock, debt securities, warrants, subscription rights, and units up to a total aggregate offering amount of $100,000,000.

Key Points: 
  • Once the registration statement becomes effective, Asset Entities may offer to the public from time to time, in one or more offerings, shares of class B common stock, preferred stock, debt securities, warrants, subscription rights, and units up to a total aggregate offering amount of $100,000,000.
  • However, Asset Entities is not selling any securities from the shelf registration statement at this time.
  • Asset Entities believes that a shelf registration on Form S-3 will provide greater flexibility to raise capital in the future.
  • Our registration statement on Form S-3 has not yet been declared effective by the SEC.

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Retrieved on: 
Thursday, May 2, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Sale, Date, Prospectus, Common, Communication, Form S-3, Pulse, Form, Exercise, Common stock, EDGAR, Eastern Time Zone, Rights, Register, Alternative, Person, Security (finance)

Only persons who own Company stock on the May 16, 2024 Record Date will be able to participate in the Rights Offering.

Key Points: 
  • Only persons who own Company stock on the May 16, 2024 Record Date will be able to participate in the Rights Offering.
  • Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $60,000,000, less expenses related to the Rights Offering.
  • As indicated below, please refer to the Registration Statement on Form S-3, as amended, for more complete information regarding the planned Rights Offering.
  • Each warrant will be exercisable immediately upon completion of the Rights Offering and will expire on the fifth anniversary of the completion of the Rights Offering.

Delek Logistics Partners, LP Increases Quarterly Cash Distribution to $1.07 per Common Limited Partner Unit

Retrieved on: 
Thursday, April 25, 2024
Energy, Other Energy, Oil, Gas, Delek, Form, Form S-3, DKL

Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today declared its quarterly cash distribution for the first quarter 2024 of $1.07 per common limited partner unit, or $4.28 per common limited partner unit on an annualized basis.

Key Points: 
  • Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today declared its quarterly cash distribution for the first quarter 2024 of $1.07 per common limited partner unit, or $4.28 per common limited partner unit on an annualized basis.
  • This distribution represents a 4.4 percent increase over Delek Logistics’ distribution for the first quarter 2023 of $1.025 per common limited partner unit ($4.10 per common limited partner unit annualized).
  • The first quarter 2024 cash distribution is payable on May 15, 2024, to unitholders of record on May 8, 2024.
  • Delek Logistics is also filing a “shelf” registration statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) to provide up to $500 million of additional financial flexibility going forward.

Mirion Announces Redemption of Public Warrants

Retrieved on: 
Thursday, April 18, 2024
Health, Defense, Energy, Government Technology, Radiology, Nuclear, Transfer, Sale, Common, MIR, Security (finance), Form S-3, Warrant, Exercise, Election, Form, Common stock, State Street, Redemption, Attention

Under the Warrant Agreement, Mirion is entitled to redeem its public warrants at a redemption price of $0.10 per warrant if the last sale price of the Common Stock equals or exceeds $10.00 per share on the trading day before the Company issues the notice of redemption (the “Stock Price Condition”), among other conditions.

Key Points: 
  • Under the Warrant Agreement, Mirion is entitled to redeem its public warrants at a redemption price of $0.10 per warrant if the last sale price of the Common Stock equals or exceeds $10.00 per share on the trading day before the Company issues the notice of redemption (the “Stock Price Condition”), among other conditions.
  • The stock price condition was satisfied on April 17, 2024, the day before the Notice of Redemption is being sent to warrant holders.
  • Warrant holders may continue to exercise their warrants to purchase shares of Common Stock until immediately before 5:00 p.m. New York City time on the Redemption Date.
  • The warrants are listed on the NYSE under the ticker symbol “MIR WS.” Any outstanding Mirion public warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be void and no longer exercisable, except to receive the Redemption Price or as otherwise described in the Notice of Redemption.